What is HC Wainwright’s Estimate for SLNO FY2024 Earnings?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) – Analysts at HC Wainwright lifted their FY2024 earnings per share estimates for Soleno Therapeutics in a research note issued on Monday, December 2nd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($3.74) for the year, up from their prior estimate of ($4.04). HC Wainwright has a “Buy” rating and a $70.00 price target on the stock. The consensus estimate for Soleno Therapeutics’ current full-year earnings is ($3.76) per share. HC Wainwright also issued estimates for Soleno Therapeutics’ Q4 2024 earnings at ($0.71) EPS, Q1 2025 earnings at ($0.71) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.78) EPS and FY2025 earnings at ($3.07) EPS.

A number of other research firms have also recently issued reports on SLNO. Robert W. Baird reissued an “outperform” rating and set a $72.00 price objective on shares of Soleno Therapeutics in a research report on Monday. Oppenheimer boosted their price target on Soleno Therapeutics from $65.00 to $73.00 and gave the stock an “outperform” rating in a research report on Monday, October 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $74.00 price target on shares of Soleno Therapeutics in a research report on Monday. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $67.00 price target on shares of Soleno Therapeutics in a research report on Friday, September 20th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $74.83.

Soleno Therapeutics Trading Down 1.0 %

SLNO opened at $50.67 on Wednesday. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of -15.26 and a beta of -1.47. Soleno Therapeutics has a 1 year low of $27.27 and a 1 year high of $60.92. The stock has a fifty day moving average price of $53.67 and a 200 day moving average price of $48.75.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($1.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.61) by ($1.22).

Hedge Funds Weigh In On Soleno Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLNO. Amalgamated Bank bought a new position in Soleno Therapeutics during the second quarter valued at about $31,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at approximately $155,000. Curi RMB Capital LLC bought a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at approximately $202,000. Intech Investment Management LLC bought a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at approximately $262,000. Finally, Fred Alger Management LLC bought a new stake in shares of Soleno Therapeutics in the 3rd quarter valued at approximately $310,000. 97.42% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Kristen Yen sold 3,108 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $49.43, for a total transaction of $153,628.44. Following the completion of the transaction, the insider now owns 81,465 shares of the company’s stock, valued at approximately $4,026,814.95. The trade was a 3.67 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James H. Mackaness sold 8,077 shares of the business’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $49.43, for a total value of $399,246.11. Following the transaction, the chief financial officer now directly owns 119,172 shares of the company’s stock, valued at $5,890,671.96. This represents a 6.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 32,818 shares of company stock valued at $1,622,194. Insiders own 12.30% of the company’s stock.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.